Want to see ENTA full AI Analyst Report?
ENTA Stock Chart & Stats
$13.80
-$0.05(-0.39%)
At close: 4:00 PM EDT
$13.80
-$0.05(-0.39%)
Day’s Range― - ―
52-Week Range$10.20 - $17.15
Previous Close$12.73
Volume91.84K
Average Volume (3M)268.00K
Market Cap
$339.89M
Enterprise Value$416.67M
Total Cash (Recent Filing)$189.51M
Total Debt (Recent Filing)$55.66M
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Nov 16, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.41
Shares Outstanding29,125,402
10 Day Avg. Volume214,007
30 Day Avg. Volume267,995
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.95
Price to Sales (P/S)3.91
P/FCF Ratio-7.94
Enterprise Value/Market Cap1.23
Enterprise Value/Revenue6.38
Enterprise Value/Gross Profit6.51
Enterprise Value/Ebitda-9.20
Forecast
1Y Price Target
$20.00Price Target Upside44.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.37
Revenue Forecast (FY)$63.74M
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginA roughly 98% gross margin indicates that Enanta’s discovery-based products and partnered economics retain substantial value after direct costs. This provides a strong foundation for future profitability if pipeline revenue expands, although operating expenses currently absorb that gross profit.
Improved LeverageMaterial debt reduction has strengthened Enanta’s balance-sheet flexibility and reduced the burden of financing obligations. Positive equity and lower leverage give management more capacity to fund development activities, withstand setbacks, and pursue partnerships without the same level of balance-sheet pressure.
RSV Pipeline ProgressAdvancing zelicapavir into a registrational Phase 2b/3 program creates a meaningful path toward a potentially important future product opportunity. Progress in respiratory antivirals could diversify Enanta beyond historical HCV economics and support future partnering, milestones, or royalties.
Bears Say
Persistent Operating LossesEnanta’s very large operating and net losses show that its current revenue base does not cover the cost of advancing and maintaining the business. Continued losses can erode equity, constrain investment in the pipeline, and delay the point at which the company becomes sustainably profitable.
Negative Cash GenerationNegative operating and free cash flow indicate that Enanta is not currently self-funding its operations or development programs. Even though the burn rate has improved from earlier periods, continued reliance on balance-sheet resources or external capital can limit strategic flexibility and increase financing dependence.
Declining RevenueThe sustained revenue decline signals limited current top-line momentum and underscores dependence on future pipeline progress or partner activity. Without renewed royalty, milestone, collaboration, or product revenue, Enanta may struggle to offset its fixed research and development cost base.
Enanta Pharmaceuticals News
ENTA FAQ
What was Enanta Pharmaceuticals’s price range in the past 12 months?
Enanta Pharmaceuticals lowest stock price was $10.20 and its highest was $17.15 in the past 12 months.
What is Enanta Pharmaceuticals’s market cap?
Enanta Pharmaceuticals’s market cap is $339.89M.
When is Enanta Pharmaceuticals’s upcoming earnings report date?
Enanta Pharmaceuticals’s upcoming earnings report date is Nov 16, 2026 which is in 25 days.
How were Enanta Pharmaceuticals’s earnings last quarter?
Enanta Pharmaceuticals released its earnings results on Aug 10, 2026. The company reported -$0.67 earnings per share for the quarter, missing the consensus estimate of -$0.51 by -$0.16.
Is Enanta Pharmaceuticals overvalued?
According to Wall Street analysts Enanta Pharmaceuticals’s price is currently Undervalued.
Does Enanta Pharmaceuticals pay dividends?
Enanta Pharmaceuticals does not currently pay dividends.
What is Enanta Pharmaceuticals’s EPS estimate?
Enanta Pharmaceuticals’s EPS estimate is -0.72.
How many shares outstanding does Enanta Pharmaceuticals have?
Enanta Pharmaceuticals has 29,125,402 shares outstanding.
What happened to Enanta Pharmaceuticals’s price movement after its last earnings report?
Enanta Pharmaceuticals reported an EPS of -$0.67 in its last earnings report, missing expectations of -$0.51. Following the earnings report the stock price went down -2.1%.
Which hedge fund is a major shareholder of Enanta Pharmaceuticals?
Currently, no hedge funds are holding shares in ENTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enanta Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (44.93% Upside)
$20.00 (44.93% Upside)
Blogger Sentiment
Neutral
ENTA Sentiment 67%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 453.7K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
4.99%
12-Months-Change
Fundamentals
Return on Equity
-61.84%
Trailing 12-Months
Asset Growth
-1.38%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
ENTA Stock 12 Month Forecast
Average Price Target
$20.00
▲(44.93% Upside)
Technical Analysis
Abeona Therapeutics
―
Tectonic Therapeutic
―
Allogene Therapeutics
―
Jade Biosciences
―
Neumora Therapeutics, Inc.
―
Ownership Overview
4.74% Insiders
13.30% Mutual Funds
35.35% Other Institutional Investors
35.00% Public Companies and
Individual Investors